Fig. 5
From: Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma
AZ and/or MS-275 inhibited tumor growth of NB xenografts. a presents the gross morphology, b H&E histology, c volume, d weight, e CD31 staining and f the percentage of CD31 positive cells after 14 days treatment with AZ and/or MS-275 compared to the untreated group in SH-SY5Y xenografts. AZ caused 13% ± 0.29%, MS-275 43% ± 0.50% and AZ + MS-275 60% ± 0.48% (p = 0.0009) inhibition in tumor growth. Tumor weights were reduced by 29 ± 0.2% (p = 0.193) for AZ, 83% ± 0.74% (p < 0.001) for MS-275 and 89.5 ± 0.49% (p < 0.001) for AZ + MS275. AZ caused a 13% ± 0.98%(p = 0.006), MS-275 a 52% ± 0.0.94% (p = 0.0008) and AZ + MS-275 a 73% ± 0.92% (p < 0.0001) decrease in the number of CD31 positive cells compared to the control